Alpine Immune Sciences (FRA:34LA) ROCE % : 9.14% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Alpine Immune Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alpine Immune Sciences's annualized ROCE % for the quarter that ended in Dec. 2023 was 9.14%.

Alpine Immune Sciences ROCE % Historical Data

The historical data trend for Alpine Immune Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences ROCE % Chart

Alpine Immune Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-91.17

-35.60

-35.22

-27.26

-11.16

Alpine Immune Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-31.20	-24.20	-25.81	-24.35	9.14

Alpine Immune Sciences ROCE % Calculation

Alpine Immune Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-29.328	/	( ( (270.632 - 54.748)	+	(348.324 - 38.496) )	/ 2 )
	=	-29.328	/	( (215.884	+	309.828)	/ 2 )
	=	-29.328	/	262.856
	=	-11.16 %

Alpine Immune Sciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	22.24	/	( ( (225.393 - 48.553)	+	(348.324 - 38.496) )	/ 2 )
	=	22.24	/	( ( 176.84	+	309.828 )	/ 2 )
	=	22.24	/	243.334
	=	9.14 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Alpine Immune Sciences (FRA:34LA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alpine Immune Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Immune Sciences (FRA:34LA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (FRA:34LA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ALPN:USA 34LA:Germany

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (FRA:34LA) Headlines

No Headlines